NASDAQ:INTS Intensity Therapeutics (INTS) Stock Price, News & Analysis $3.58 -0.20 (-5.40%) As of 01:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Intensity Therapeutics Stock (NASDAQ:INTS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Intensity Therapeutics alerts:Sign Up Key Stats Today's Range$3.66▼$3.8350-Day Range$3.77▼$6.0052-Week Range$3.65▼$43.50Volume17,138 shsAverage Volume42,673 shsMarket Capitalization$9.67 millionP/E RatioN/ADividend YieldN/APrice Target$37.50Consensus RatingModerate Buy Company Overview Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut. Read More Intensity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreINTS MarketRank™: Intensity Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 360th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingIntensity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialIntensity Therapeutics has a consensus price target of $37.50, representing about 898.9% upside from its current price of $3.75.Amount of Analyst CoverageIntensity Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Intensity Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intensity Therapeutics are expected to grow in the coming year, from ($2.70) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intensity Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intensity Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntensity Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Intensity Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.00% of the float of Intensity Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics has a short interest ratio ("days to cover") of 2.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics has recently increased by 3.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntensity Therapeutics does not currently pay a dividend.Dividend GrowthIntensity Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest3 people have searched for INTS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Intensity Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.10% of the stock of Intensity Therapeutics is held by insiders.Percentage Held by Institutions3.74% of the stock of Intensity Therapeutics is held by institutions.Read more about Intensity Therapeutics' insider trading history. Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INTS Stock News HeadlinesIntensity Therapeutics (INTS) & Its Rivals Critical ReviewMay 29, 2026 | americanbankingnews.comIntensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical AwardMay 14, 2026 | prnewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.June 9 at 1:00 AM | Banyan Hill Publishing (Ad)Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | prnewswire.comIntensity Therapeutics (INTS) price target decreased by 12.76% to 49.98April 28, 2026 | msn.comIntensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare InnovationApril 15, 2026 | prnewswire.comIntensity Therapeutics (INTS) price target decreased by 11.32% to 57.29April 9, 2026 | msn.comIntensity Therapeutics (INTS) price target decreased by 13.14% to 64.60March 28, 2026 | msn.comSee More Headlines INTS Stock Analysis - Frequently Asked Questions How have INTS shares performed this year? Intensity Therapeutics' stock was trading at $10.05 at the start of the year. Since then, INTS shares have decreased by 62.6% and is now trading at $3.7540. How were Intensity Therapeutics' earnings last quarter? Intensity Therapeutics Inc. (NASDAQ:INTS) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.13. When did Intensity Therapeutics' stock split? Intensity Therapeutics's stock reverse split on the morning of Thursday, February 19th 2026.The 1-25 reverse split was announced on Friday, February 13th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 18th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Intensity Therapeutics IPO? Intensity Therapeutics (INTS) raised $18 million in an IPO on Friday, June 30th 2023. The company issued 3,900,000 shares at $4.00-$5.00 per share. How do I buy shares of Intensity Therapeutics? Shares of INTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intensity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ). Company Calendar Last Earnings5/07/2026Today6/09/2026AGM 20266/16/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 INTS's financial health is in the Red zone, according to TradeSmith. INTS has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:INTS CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Price Target for Intensity Therapeutics$37.50 High Price Target$37.50 Low Price Target$37.50 Potential Upside/Downside+920.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($5.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-136.82% Return on Assets-105.82% Debt Debt-to-Equity Ratio0.01 Current Ratio4.86 Quick Ratio4.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book0.74Miscellaneous Outstanding Shares2,703,000Free Float2,511,000Market Cap$9.93 million OptionableNot Optionable Beta2.77 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:INTS) was last updated on 6/9/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
